Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives $9.50 Average PT from Analysts

Shares of Quince Therapeutics, Inc. (NASDAQ:QNCXGet Free Report) have received an average recommendation of “Buy” from the six brokerages that are presently covering the company, Marketbeat reports. Four equities research analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $9.50.

A number of research firms recently issued reports on QNCX. D. Boral Capital reiterated a “buy” rating and set a $12.00 target price on shares of Quince Therapeutics in a research report on Thursday, January 2nd. Rodman & Renshaw assumed coverage on shares of Quince Therapeutics in a research report on Tuesday, October 29th. They set a “buy” rating and a $11.00 price objective on the stock. RODMAN&RENSHAW raised Quince Therapeutics to a “strong-buy” rating in a research report on Tuesday, October 29th. EF Hutton Acquisition Co. I upgraded Quince Therapeutics to a “strong-buy” rating in a report on Tuesday, October 22nd. Finally, Brookline Capital Management initiated coverage on Quince Therapeutics in a research report on Wednesday, December 18th. They set a “buy” rating and a $9.00 target price on the stock.

Read Our Latest Analysis on Quince Therapeutics

Quince Therapeutics Trading Up 2.5 %

NASDAQ QNCX opened at $1.64 on Monday. Quince Therapeutics has a one year low of $0.51 and a one year high of $2.45. The company has a debt-to-equity ratio of 0.33, a current ratio of 9.53 and a quick ratio of 9.53. The business has a 50 day simple moving average of $1.86 and a 200 day simple moving average of $1.23. The stock has a market capitalization of $72.16 million, a P/E ratio of -1.32 and a beta of 0.64.

Institutional Trading of Quince Therapeutics

An institutional investor recently bought a new position in Quince Therapeutics stock. Scharf Investments LLC acquired a new position in shares of Quince Therapeutics, Inc. (NASDAQ:QNCXFree Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 91,061 shares of the company’s stock, valued at approximately $170,000. Scharf Investments LLC owned approximately 0.21% of Quince Therapeutics as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 30.75% of the company’s stock.

About Quince Therapeutics

(Get Free Report

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.

Recommended Stories

Analyst Recommendations for Quince Therapeutics (NASDAQ:QNCX)

Receive News & Ratings for Quince Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quince Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.